Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Thursday 16 January, 2020

AIM

Schedule One Update - Open Orphan PLC

RNS Number : 0602A
AIM
16 January 2020
 

 

ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM RULES")


COMPANY NAME:

Open Orphan plc

 

COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES) :

Registered Office:

 

PO Box W1J 6BD, Berkley Square House, 2nd Floor, Mayfair, London, W1J 8DJ

 

Trading Offices:

 

19 Railway Road, Dalkey, Dublin, Ireland

Queen Mary BioEnterprises (QMB) Innovation Centre, 42 New Road, London, E1 2AX

 

COUNTRY OF INCORPORATION:

England and Wales

 

COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26:

www.openorphan.com

 

COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING POLICY).  IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED:

This is a reverse takeover under Rule 14.

 

Open Orphan is a Clinical Research Organisation that specialises in rare and orphan drugs. The headquarters are in Dublin, Ireland and the company also has offices in the UK, France, the Netherlands and Germany.

 

DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where known, number and type of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares):

Number of ordinary shares of 0.1 pence each in nominal value ("Ordinary Shares") for which Admission will be sought: 445,622,374

 

There are no restrictions as to the transferability of the Ordinary Shares and no Ordinary Shares will be held in treasury.

 

CAPITAL TO BE RAISED ON ADMISSION (AND/OR SECONDARY OFFERING) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION:

Expected Market Capitalisation: £29.6 million (based on an enlarged share capital of 445,622,374 and closing price per Open Orphan Shares of £0.0665 on 15 January 2020)

 

No capital to be raised on admission

PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION:

22.8%

 

DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM SECURITIES (OR OTHER SECURITIES OF THE COMPANY) ARE OR WILL BE ADMITTED OR TRADED:

Euronext Growth

 

FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or including any other name by which each is known):

Directors

Cathal Friel, Executive Chairman

Brendan Buckley, Non-executive Director

 

Proposed Directors

Dr Trevor Phillips, Chief Executive Officer

Dr Mark Warne, Non-executive Director

Michael Meade, Non-executive Director

 

FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known):

Before Admission:

 

Name

Number of Ordinary Shares

Percentage of issued share capital

Cathal Friel

41,046,981

16.1%

Anthony (Tony) Richardson

16,313,388

6.4%

Gresham House Asset Management

13,081,337

5.1%

Crux Asset Management

11,928,571

4.7%

Brendan Buckley

7,845,860

3.1%

 

 

After Admission:

 

Name

Number of Ordinary Shares

Percentage of issued share capital

Cathal Friel

41,046,981

9.2%

Anthony (Tony) Richardson

16,313,388

3.7%

Gresham House Asset Management

13,081,337

2.9%

Crux Asset Management

11,928,571

2.7%

Brendan Buckley

7,845,860

1.8%

Invesco Ltd

52,485,973

11.8%

Link Fund Solutions Ltd

38,618,608

8.7%

IP Group plc

32,267,791

7.2%

Jupiter Asset Management Ltd

22,819,579

5.1%

 

 

 

NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:

n/a

 

(i)         ANTICIPATED ACCOUNTING REFERENCE DATE

(ii)        DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited interim financial information)

(iii)       DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19:

(i)   31 December

(ii)  31 December 2019

(iii) 31 December 2019 due 30 June 2020, 30 June 2020 due September 2020, 31 December 2020 due 30 June 2021

 

EXPECTED ADMISSION DATE:

20 January 2020

 

NAME AND ADDRESS OF NOMINATED ADVISER:

Arden Partners plc

125 Old Broad Street

London

EC2N 1AR

 

NAME AND ADDRESS OF BROKER:

Arden Partners plc

125 Old Broad Street

London

EC2N 1AR

 

 

OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:

A copy of the admission document containing full details about the applicant and the admission of its securities is available on the Company's website, www.openorphan.com

 

THE CORPORATE GOVERNANCE CODE THE APPLICANT HAS DECIDED TO APPLY

The QCA Corporate Governance Code 2018 published by the Quoted Companies Alliance

 

DATE OF NOTIFICATION:

16 January 2020

 

NEW/ UPDATE:

UPDATE

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
AIMUNRURRKUAAAR

a d v e r t i s e m e n t